Shares of Summit Therapeutics plummeted 14% on Monday, trading at $12.16, after the US Food and Drug Administration (FDA) issued a refusal to approve the company’s experimental lung cancer treatment, ivonescimab. The federal regulator denied the application on Sunday, citing the drug's inability to achieve statistically significant overall survival benefits during a late-stage study that formed part of the company's submission.
Summit had sought approval to use ivonescimab in combination with chemotherapy for patients previously treated for advanced non-squamous non-small cell lung cancer (NSCLC) with EGFR mutations. These specific cases account for approximately 10% to 15% of lung cancer diagnoses within the United States.
The company previously faced scrutiny over clinical trial data that suggested higher survival benefits in Chinese patients compared to those in North America and Europe. While Summit subsequently submitted results from a longer follow-up study that it claimed showed consistent improvement across both Western and Asian populations, the regulator remained unconvinced for this specific application.
BMO Capital analyst Evan Seigerman noted that the FDA's decision establishes a significant regulatory precedent for this class of drugs. The outcome may carry implications for other pharmaceutical companies currently developing similar treatments, including Bristol Myers Squibb, BioNTech, Pfizer, Merck, and AbbVie.
Key facts
- Summit Therapeutics shares fell 14% to $12.16 in Monday morning trading.
- The FDA declined approval for ivonescimab, citing a lack of statistically significant overall survival data.
- Ivonescimab targets proteins PD-1 and VEGF to help inhibit tumor growth and spread.
- The application concerned patients with advanced NSCLC who possess EGFR mutations.
- Summit originally acquired rights to the drug from China’s Akeso in 2022.
Why it matters
Market observers and medical experts are shifting their focus to upcoming global late-stage trial data expected later this year. This study evaluates ivonescimab against Merck's established therapy, Keytruda, as a first-line treatment for NSCLC.
Analysts at TD Cowen suggested that the recent FDA rejection does not necessarily harm the drug's potential in the first-line setting, which represents a larger and more critical commercial opportunity. Oncologists continue to express interest in the PD-(L)1/VEGF drug class, noting its potential to change clinical practice for patients whose tumors do not carry EGFR mutations.
Source: Economic Times
Comments